Mark Surrey, MD

Dr. Surrey is one of the pioneers of In-Vitro Fertilization and  		Embryo Replacement. He trained in England and assisted in creating the  		first successful program there. He is also an Associate Professor at  		UCLA and an internationally recognized educator and speaker.

The file you requested will begin playing automatically.         If it does not, press the 'play' button. If you experience playback         problems, make certain you have the latest version of RealPlayer,         available 

Articles

OBGYN.net Conference CoverageSLS, Society of Laparoendoscopic Surgeons Annual Meeting 13th International Congress and Endo ExpoSeptember 29-October 2, 2004 - New York, New York

Introduction to Preimplantation Genetic Diagnosis (PGD)

The file you requested will begin playing automatically. If it does not, press the 'play' button. If you experience playback problems, make certain you have the latest version of Windows Media Player, available 

click             here for RealAudio/Video version

"The question has been       raised as to the impact and relevance of minimal endometriosis, how it's       managed, and what its implications are for the infertile female. It is       indeed a very controversial issue. The significance of it is much in       doubt, particularly when it does not seem to relate to the mechanics of       tubo-ovarian pick-up. However, there's been some information suggesting       that there certainly is a correlation with decreased fertility rates and       minimal endometriosis.
       
       There are some older studies, which suggests that there's the same impact       in minimal disease as there is in moderate disease, the perspective of       fertility rates before and after therapy. And for that reason, we treat       minimal endometriosis and moderate disease in much the same way, in so       much as that we initially surgically de-bulk it. With minimal disease we       attempt to excise it, first to make a histological diagnosis of the       suspected lesions themselves. In addition we attempt to get some histology       from areas of the peritoneum, proximate to the suspected lesions, from the       perspective of how to then subsequently manage the patient. Management, I       think, can be divided into four categories post-operatively.
       
       One would be expectant management - where you essentially do nothing. The       second would be some form of medical therapy, ranging from GnRH agonists       therapy to ovulation suppression with a progestational based combinational       contraceptive. The third management is a controlled ovarian stimulation       rationale, particularly perhaps for older women who have an increased       infertility rate. And the fourth management, I think, would be one of the       assisted reproductive procedures, specifically since you've just done a       laparoscopy, perhaps some vitro-fertilization.
       
       I think the management largely needs to be individualized depending upon a       number of different issues. The aggressiveness of which, I think, would be       determined in part by the patient's age, in so much as we will manage a       40-year-old patient with minimal endometriosis much more aggressively than       we'll manage a 30-year-old with minimal disease. I think the 30-year-old       we would be more inclined to manage expectantly and the 40-year-old more       aggressively. There has been a lot of controversy recently as to whether       patients with minimal disease require or benefit by medical therapy       postoperatively. There are a certain percentage of physicians that are       assuming this could be a systemic disease and the local manifestations of       that disease are sort of "the tip of the ice berg". They tend to       want to manage all patients medically regardless of the appearance       laparoscopically of the disease. On the other hand, if there's no other       evidence of disease present, it's probably - particularly in the older       patient - not rational to give them any significant amount of time of       postoperative suppression.
       
       So I think that it's a question that is a bit of an enigma to us       clinically. We don't have a good handle on any set management scheme, and       I think there's a certain art to medicine that comes in here in       individualizing all of the treatment of your patient with minimal       endometriosis."

OBGYN.net Conference CoverageFrom 5th International Symposium on GnRH Analogues in Cancer and Human Reproduction in Geneva, Switzerland

Treatment of Minimal Endometriosis

The file you requested will begin playing automatically.  If it does not, press the 'play' button.   If you experience playback problems, make certain you have the latest version of RealPlayer, available 

GnRH Agonist and Addback Therapy

click here for             RealAudio/Video version

"Hi, this is Mark Surrey       from Los Angeles. We're speaking from the ISGE meeting in Montreal,       Canada, in regard to some of the newer advances in operative endoscopy.       This particular meeting, we're going to address some of the results that       we've had from the procedure described as transvaginal hydrolaparoscopy,       which is a minimally invasive process utilized to evaluate the adnexa in       the infertility patient. This is a procedure performed by inserting a       dilating Veress cannula through the cul-de-sac in the midline, flooding       the peritoneum with saline, approximately 200-300 cc's, and evaluating       through a 2.7 mm lens laparoscope the peritoneal findings. We're going to       be addressing the complications of this procedure as such, as that we've       reviewed our data and the data from two large European centers in       Dusseldorf, Germany and in Leven, Belgium. What we've found is       approximately a 1% incidence of rectal perforations, and essentially no       incidence of ureteral or general urinary perforations, and no significant       incidence of vascular perforations. The rectal perforations that have been       reported have all been pre- or retroperitoneal, and therefore, have been       managed conservatively with antibiotics - none of which have required any       additional surgical procedure, and six-month follow-up on these patients       have revealed no additional complications. In conclusion, we feel that so       far the complications reported from this procedure are well within the       range of those reported from traditional transabdominal laparoscopic       approach, and therefore, this seems to be a process that we see a bright       future for. 

OBGYN.net Conference CoverageFrom ISGE - Montreal, Canada - April, 1999

Recent Results of ongoing THL studies

"Hi, I'm Mark Surrey from Los       Angeles, California, speaking to you from Montreal, Canada, once again       about some of the clinical implications of a procedure called transvaginal       hydrolaparoscopy. We have been utilizing this as a primary diagnostic       procedure to essentially replace indirect radiologic procedures like       hysterosalpingograms by moving up the time frame between diagnoses and       therapy for the infertility patients. In particular, this applies to older       patients, where we have clearly shown, as have other authors, a poor       correlation between the clinical findings of hysterosalpingography for       evaluation of the tubal factor and laparoscopy.

Traditionally, laparoscopy has been thought of as a somewhat invasive       procedure, however, requiring general anesthesia, intubation, and       outpatient hospital format. Thus, if we can offer patients a less       invasive, cost-effective process by which we can develop and gather more       information about the distal tubo-ovarian hiatus and, therefore, the tubo-ovarian       pick-up mechanism, we can triage patients - particularly the older       patients - to either IVF or controlled ovarian stimulation in a more rapid       and more appropriate fashion. Therefore, we speed up the time between a       diagnostic procedure and the appropriate therapy. As we have shown and       seen       in IVF statistics, advancing maternal age has a significant adverse effect       on fertility and, thus, anything we can do to minimize the time between       diagnosis and therapy is going to be a great benefit to these patients.

Mark Surrey, MD

Articles

Introduction to Preimplantation Genetic Diagnosis (PGD)

Introduction to Preimplantation Genetic Diagnosis (PGD)

Treatment of Minimal Endometriosis

GnRH Agonist and Addback Therapy

Recent Results of ongoing THL studies

Clinical implications of THL